Seven-year-old Wyatt Torres had his dream of going to Disneyland come true earlier this month, courtesy of Make-A-Wish.

Acute myeloid leukaemia, or AML, is an aggressive blood cancer and requires immediate attention. AML is treatable with various approaches, depending on the patient's age and health status.

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Cops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

A seven-year-old boy is thriving at school after spending almost half his life having cancer treatment. Jackson Hall, from Sutton, was diagnosed with leukaemia five years ago this month. He was two ...

zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

A seven-year-old boy is thriving at school after spending almost half his life having cancer treatment. Jackson Hall, from Sutton, was diagnosed with leukaemia five years ago this month.